Tickers

1. Composite Trajectory Verdict

The income statement carries the most weight for assessing ITGR's performance because the company's contract manufacturing model translates revenue volume and mix directly into margin dynamics, and the recent quarter shows a sharp inflection in profitability that the annual data alone would mask.

Composite Trajectory: Mixed

Annual results through 2025 show revenue growth (8% YoY to $1.854B), stable gross margins (27.0% vs 26.7%), and operating income growth (6% to $221M), but GAAP income from continuing operations fell 15% to $102.8M due primarily to a $46.7M induced conversion expense from the 2028 Notes exchange (10-K 2025, Consolidated Statements of Operations). Quarterly Q2 2026 reveals a sharp deterioration: sales declined 2.6% YoY to $464.1M, gross margin compressed 280 bps to 24.3%, operating margin fell 510 bps to 7.4%, and income from continuing operations dropped 36% to $23.6M (10-Q 2026-07-03, Condensed Statements of Operations). Cash generation remains solid annually but the balance sheet shows rising leverage and a cash build consumed by acquisitions and buybacks.

2. Red Flags

• GAAP earnings distorted by large one-time debt exchange cost: Other loss, net jumped from $3.5M (2024) to $53.2M (2025) due to a $46.7M induced conversion expense, turning a 15% pre-tax income decline into a 15% net income decline despite higher operating income (10-K 2025, Consolidated Statements of Operations).
• Q2 2026 margin collapse: Gross margin fell to 24.3% from 27.1% in Q2 2025; operating margin fell to 7.4% from 12.5%; restructuring charges surged to $9.4M from $2.7M (10-Q 2026-07-03, Condensed Statements of Operations).
• Revenue decline tied to new product adoption: Q2 2026 sales dropped $12.4M YoY, explicitly attributed to "lower than anticipated market adoption" of three new products (10-Q 2026-07-03, MD&A).
• Debt principal up 21% with cash drawn down: Total debt principal rose from $1.001B to $1.207B; cash fell from $46.5M to $17.2M after $178.9M in acquisitions, $91.0M cap ex, and $50.0M share repurchases (10-K 2025, Consolidated Balance Sheets; 10-K 2025, Consolidated Statements of Cash Flows).
• Accounts receivable growth outpaces sales: Receivables rose 41% to $346.1M while sales rose 8%; MD&A cites lower factoring volume and timing of payments (10-K 2025, MD&A Liquidity).
• Pending go-private merger: Agreement announced Aug 2, 2026 at $127/share introduces termination risk ($154M fee) and delisting (10-Q 2026-07-03, MD&A The Merger).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP income from continuing operations declined 15% to $102.8M in 2025 from $121.1M in 2024, but operating income rose 6% to $221.3M on 8% sales growth (10-K 2025, Consolidated Statements of Operations). The divergence is almost entirely explained by the $46.7M induced conversion expense recorded in Other loss, net. Excluding that item, pre-tax income would have been approximately $172M vs $147.6M in 2024. Gross margin improved 30 bps to 27.0%; operating margin slipped 20 bps to 11.9% as SG&A rose 14% and restructuring charges rose 47% (10-K 2025, MD&A). Quarterly Q2 2026 shows a clear downturn: sales -2.6%, gross margin -280 bps, operating margin -510 bps, and income from continuing operations -36% YoY (10-Q 2026-07-03, Condensed Statements of Operations). Six-month 2026 income from continuing operations rose to $40.1M from $14.5M in the prior year, but the comparison is distorted by a weak Q1 2025 (not separately provided) and the Q2 2026 decline (10-Q 2026-07-03, MD&A).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Stable

Operating cash flow has been consistent: $180.2M (2023), $205.2M (2024), $196.1M (2025) (10-K 2025, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less cap ex) improved sequentially: $60.3M, $99.8M, $105.1M. Investing cash outflows increased due to acquisitions: $43.6M (2023), $138.5M (2024), $178.9M (2025) (10-K 2025, Consolidated Statements of Cash Flows). Financing turned positive in 2025 ($43.6M) from the $1.0B convertible notes issuance, which funded the 2028 Notes exchange, capped calls ($71M), debt paydowns, and the $50M share repurchase (10-K 2025, Consolidated Statements of Cash Flows). Net cash declined $29.4M in 2025 to $17.2M, but revolver availability remains $794.7M (10-K 2025, MD&A Liquidity). Quarterly cash flow details for 2026 are not provided in the excerpts.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew 11% to $3.41B driven by goodwill (+$93M to $1.11B) and intangibles (+$47M to $825M) from the three 2025 acquisitions (10-K 2025, Consolidated Balance Sheets). Total debt principal increased 21% to $1.207B, but the fixed-rate share rose from ~50% to ~92% after the 2030 Notes issuance (10-K 2025, MD&A Interest Expense). Net leverage is 2.7x with interest coverage of 13.6x (10-K 2025, MD&A Credit Facilities). Current ratio improved to 3.32x from 2.95x; working capital rose to $538M from $444M (10-K 2025, MD&A Liquidity). Cash is low at $17.2M but supported by an undrawn $800M revolver. Contingent consideration liabilities jumped to $8.2M from $0.9M, with $7.0M due in 2026 (10-K 2025, Note 18). The pending merger adds uncertainty to capital structure.

6. Data Gaps

• Q1 2026, Q3 2025, Q1 2025, and Q4 2025 standalone quarterly income statements and cash flow statements (needed to confirm six-month trends and quarterly seasonality)
• Q2 2026 cash flow statement (to assess if operating cash flow deterioration matches earnings decline)
• Segment-level quarterly sales by product line for 2026 quarters (only annual and Q2 2026 aggregate provided)
• Full 2026 capital expenditure and acquisition spending run-rate (only annual 2026 guidance of $95-105M cap ex given)
• Post-merger balance sheet pro forma (merger announced after Q2 2026 filing)